Catalent to Acquire Accucaps


Catalent has agreed to acquire softgel manufacturer Accucaps Industries Ltd. Financial details of the transaction were not disclosed, but analysts that follow Catalent put the price at $75 million, representing a multiple of 10x EBITDA. The deal is subject to Canadian regulatory approval.

Accucaps is owned by Canadian generic pharmaceutical company Apotex, a detail not mentioned in Catalent’s announcement. The company has two facilities, in Windsor and Strathroy, Ontario, and claims to have capacity to manufacture 10-12 billion softgel capsules/year. It develops, manufactures and packages softgel products for both the prescription and OTC markets. It has over 500 employees, and PharmSource estimates its revenues to be in the $75-100 million range.

Accucaps has capabilities to manufacture high potency softgel products. In 2014, it opened a new high potency suite at its Windsor facility, in which it had invested $5 million. The company launched its first-ever high potency product out of the new suite. The company moved into the current 108,000-square-foot Strathroy facility in 2013.

This article is reprinted from the December issue of Bio/Pharmaceutical Outsourcing Report. The full article addresses Catalent’s authority in the contract softgel manufacturing segment. To learn more, click here.

Related posts:
Growing Turkish Pharma Market Attracts Investment Despite Challenges
Five Themes That Will Drive the CMO Industry
Trial Registrations Reflect Improved Funding

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller